熱門資訊> 正文

I-Mab Bizerma GAAP每股收益为-0.48美元

2026-04-08 05:26

新橋生物(NBP) 0

I-Mab Biopharma press release (NBP): FY GAAP EPS of -$0.48.
As of December 31, 2025, the Company had cash, cash equivalents, and short-term investments of $210.8 million. The Company’s current cash position is expected to support operations through 2028.

More on I-Mab Biopharma

NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration - Slideshow
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript
Seeking Alpha’s Quant Rating on I-Mab Biopharma
Historical earnings data for I-Mab Biopharma
Financial information for I-Mab Biopharma

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。